Company / Cash per Share
CRISPR Therapeutics AG Cash per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$4.05
FY2025
5-year range
$2.75 / $12.49
FY2021-FY2025
Trend
+8.8%
vs FY2024
Sector context
#51 of 207
Health Care
What the data says
CRISPR Therapeutics AG's cash per share of $4.05 is higher than 75% of companies in the Health Care sector (FY2025). Cash per Share has fluctuated over the past 10 years, ranging from $2.75 in FY2022 to $57.08 in FY2016.
Based on SEC 10-K filings.
4.05 in FY2025 with a 5-year CAGR of -26.8%. Top quartile in the Health Care sector.
Declined from $4.96 to $4.05 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- +13.8%
- 5-Year CAGR
- -26.8%
- 10-Year CAGR
- -
Sector benchmark
-94.0% below sector average
Key checks
Key Insights
- In FY2025, cash per share increased 8.8% year-over-year.
- Ranks #51 out of 207 companies in the Health Care sector.
- Peak cash per share was recorded in FY2016.
- Lowest cash per share in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.05 | +8.8% |
| FY2024 | $3.73 | -24.9% |
| FY2023 | $4.96 | +80.3% |
| FY2022 | $2.75 | -78.0% |
| FY2021 | $12.49 | -35.0% |
| FY2020 | $19.23 | +5.6% |
| FY2019 | $18.20 | +61.8% |
| FY2018 | $11.25 | +86.4% |
| FY2017 | $6.04 | -89.4% |
| FY2016 | $57.08 | +84.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026